<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Thromb J</journal-id><journal-title>Thrombosis Journal</journal-title><issn pub-type="epub">1477-9560</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1477-9560-7-9</article-id><article-id pub-id-type="pmid">19538716</article-id><article-id pub-id-type="doi">10.1186/1477-9560-7-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Basic Research</subject></subj-group></article-categories><title-group><article-title>Thrombotic genetic risk factors and warfarin pharmacogenetic variants in S&#x000e3;o Miguel's healthy population (Azores)</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Branco</surname><given-names>Claudia C</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>claudiacbranco@hdes.pt</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Pereirinha</surname><given-names>T&#x000e2;nia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>taniapereirinha@hdes.pt</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Cabral</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ritacabral@hdes.pt</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Pacheco</surname><given-names>Paula R</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>paularpacheco@hdes.pt</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Mota-Vieira</surname><given-names>Luisa</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>lmotavieira@hdes.pt</email></contrib></contrib-group><aff id="I1"><label>1</label>Molecular Genetics and Pathology Unit, Hospital of Divino Espirito Santo of Ponta Delgada, EPE, S&#x000e3;o Miguel Island, Azores, Portugal</aff><aff id="I2"><label>2</label>Instituto Gulbenkian de Ci&#x000ea;ncia, Oeiras, Portugal</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2009</year></pub-date><volume>7</volume><fpage>9</fpage><lpage>9</lpage><ext-link ext-link-type="uri" xlink:href="http://www.thrombosisjournal.com/content/7/1/9"/><history><date date-type="received"><day>5</day><month>12</month><year>2008</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Branco et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Branco et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Branco C Claudia claudiacbranco@hdes.pt </dc:author><dc:title> Thrombotic genetic risk factors and warfarin pharmacogenetic variants in S&#x000e3;o Miguel's healthy population (Azores) </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Thrombosis Journal 7(1): 9-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-9560(2009)7:1&#x0003c;9&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-9560</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The Azorean population presents the highest standardized mortality rate for cardiovascular diseases (CVD) when compared to mainland Portugal and other populations. Since thrombosis is a common cause of CVD, we assessed four polymorphisms in three thrombotic risk genes &#x02013; <italic>F5 </italic>(G1691A), <italic>F2 </italic>(G20210A) and <italic>MTHFR </italic>(C677T, A1298C), in 469 healthy blood donors from S&#x000e3;o Miguel Island (Azores). We also analysed the <italic>CYP2C9 </italic>(C430T, A1075C) and <italic>VKORC1 </italic>(G1639A) variants in fifty-eight individuals with predisposition to thrombosis (possessing at least one variation in <italic>F5 </italic>or <italic>F2 </italic>genes and one in <italic>MTHFR</italic>) to evaluate their warfarin drug response genetic profiles.</p></sec><sec><title>Results</title><p>Among the 469 individuals, the data showed that thrombotic risk allele frequencies &#x02013; 1691A (4.9%), 20210A (1.8%), 677T (41.7%) and 1298C (24.8%) &#x02013; were similar to other Caucasians, but significantly different from mainland Portuguese (&#x003c7;<sup>2</sup>, <italic>p </italic>&#x0003c; 0.001). The combined analysis of these variants identified twenty-two different genetic profiles (genotype order: <italic>F5</italic>, <italic>F2</italic>, <italic>MTHFR </italic>C677T and A1298C). Complete homozygosity for all wild-type alleles (GG GG CC AA) was present in 11.7%, being GG GG CT AA (22.4%) the most frequent profile. The results also demonstrated that 12.4% (58 out of 469) of S&#x000e3;o Miguel islanders have increased genetic predisposition to thrombosis. Subsequently, we evaluated these individuals for their warfarin response genetic profiles. The data showed that seven out of fifty-eight individuals are poor metabolizers (two with <italic>CYP2C9</italic>*2/*2 and five with <italic>CYP2C9</italic>*2/*3 genotypes). <italic>VKORC1 </italic>polymorphism analysis identified twelve individuals (20.7%) with AA genotype, who probably will require lower doses of warfarin. The joint analysis of <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>revealed that 79.3% (46 out of 58) of the individuals carry at least one polymorphism in these genes. Within these, twenty-five individuals (43.1%) need intermediate and/or low doses of warfarin, if treatment is started.</p></sec><sec><title>Conclusion</title><p>The present study demonstrated, for the first time, that S&#x000e3;o Miguel, and possibly the Azores population, shows significant differences on allele frequencies of thrombotic risk factors when compared to mainland Portugal. This research constitutes a primary approach for future studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's genotypic information.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Cardiovascular diseases (CVD) are complex disorders that include dysfunctional conditions of the heart, arteries and veins. Within these diseases, thrombosis is the third most common cardiovascular event worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. It can derive from: i) genetic factors; ii) acquired changes in the clotting mechanism; and iii) more commonly, interaction between the two factors described above [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. The main hereditary form of thrombosis is caused by the G1691A variation in the factor V Leiden gene (<italic>F5</italic>; 1q23), resulting in resistance to activated protein C (APC). In the coagulation biochemical pathway, APC prevents blood clots from growing extensively large, by inactivating coagulation factor V (encoded by <italic>F5</italic>). The G1691A variation may increase the risk for thrombosis by 8 and 91 in heterozygous and homozygous states, respectively [<xref ref-type="bibr" rid="B5">5</xref>]. According to Poort <italic>et al. </italic>[<xref ref-type="bibr" rid="B6">6</xref>], prothrombin (<italic>F2</italic>; 11p11-q12) represents the second most important inherited thrombotic risk factor. A single base substitution (G20210A) in the <italic>F2 </italic>3'-untranslated region causes elevated plasma prothrombin levels. The same authors reported a 2.8-fold increase risk for venous thrombosis in heterozygous and homozygous variant individuals [<xref ref-type="bibr" rid="B6">6</xref>]. Other reported gene involved in thrombosis, the methylenetetrahydrofolate reductase (<italic>MTHFR</italic>; 1p36.3), includes two variants &#x02013; C677T and A1298C [<xref ref-type="bibr" rid="B7">7</xref>]. The 677T alters the protein's folate binding site and lowers the enzymatic activity of MTHFR. As consequence, patients have elevated plasma levels of total homocysteine (tHcy) [<xref ref-type="bibr" rid="B8">8</xref>]. The 1298C variant also decreases the enzymatic activity of MTHFR, which is more pronounced in homozygous variant than in heterozygous state [<xref ref-type="bibr" rid="B8">8</xref>]. According to Heijer <italic>et al. </italic>[<xref ref-type="bibr" rid="B9">9</xref>], individuals with the 677TT genotype show a 15% (OR = 1.1; 95% CI = 1.0&#x02013;1.3) increased risk for venous thromboembolism (VTE) in Europe. Additionally, Klerk <italic>et al. </italic>[<xref ref-type="bibr" rid="B10">10</xref>] reported an OR of 1.3 (95% CI = 1.1&#x02013;1.5) for the 677CT genotype.</p><p>The genetic characterization of the individual's potential risk for developing thrombosis and response to drugs is essential in clinical follow-ups, as well as for medical prescription. Warfarin is one of the most widely used anticoagulant drug, which requires a thorough risk-benefit analysis since the dose prescribed should avoid hemorrhagic complications and achieves suppression of thrombosis [<xref ref-type="bibr" rid="B11">11</xref>]. The administrated drug is a racemic mixture of S- and R-enantiomers, having S- the majority of the therapeutic effect [<xref ref-type="bibr" rid="B12">12</xref>]. Warfarin pharmacogenetic studies demonstrated that variants in the <italic>CYP2C9 </italic>(Cytochrome P450 2C9) and <italic>VKORC1 </italic>(Vitamin K epoxide reductase complex subunit 1) genes account for approximately 50&#x02013;60% of drug dosing variability [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Cytochrome P450 2C9 is the major enzyme responsible for metabolising the active S-enantiomer [<xref ref-type="bibr" rid="B12">12</xref>]. Although there are many polymorphisms in <italic>CYP2C9</italic>, the most frequent variants are: <italic>CYP2C9</italic>*1 (Arg144/Ile359, wild-type), <italic>CYP2C9</italic>*2 (Arg144Cys) and <italic>CYP2C9</italic>*3 (Ile359Leu). These last two are associated with decreased metabolic efficiency of the CYP2C9 enzyme and increased risk of bleeding when administrated initial dosages of warfarin [<xref ref-type="bibr" rid="B15">15</xref>]. A G&#x0003e;A variation at position 1639 in the promoter region of the <italic>VKORC1 </italic>gene results in decreased mRNA transcription and increased sensitivity to warfarin inhibition of hepatic synthesis of functional vitamin K-dependent coagulation factors [<xref ref-type="bibr" rid="B13">13</xref>]. Rieder <italic>et al. </italic>[<xref ref-type="bibr" rid="B13">13</xref>] studied <italic>VKORC1 </italic>polymorphisms and classified individuals according to warfarin dose requirements into distinct groups: high (GG), intermediate (GA) and low (AA).</p><p>The Azores population presents the highest standardized mortality rate caused by CVD when compared to mainland Portugal (Portuguese General Directorate of Health) [<xref ref-type="bibr" rid="B16">16</xref>] and other populations. Since thrombosis is a known cause of CVD, the present research aims to assess, in the S&#x000e3;o Miguel healthy population, the allelic variants and genotypes of three genes &#x02013; <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>&#x02013; involved in blood clot formation. Moreover, in the individuals with predisposition to thrombosis, we evaluated the pharmacogenetic profile for warfarin, by characterizing <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>polymorphisms. This information is important for the implementation of warfarin pre-prescription genotyping with the goal of performing individualized treatment.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Population sample</title><p>The population sample comprised a group of 469 S&#x000e3;o Miguel Island blood donors from the anonymized Azorean DNA bank located in the main Hospital of Azores archipelago, Portugal [<xref ref-type="bibr" rid="B17">17</xref>]. S&#x000e3;o Miguel, the largest island in this archipelago, has 131,609 inhabitants (54.4% of the Azoreans; 2001 Census, Portugal National Institute of Statistics) [<xref ref-type="bibr" rid="B18">18</xref>]. In this group we analysed four polymorphisms in three thrombotic predisposition genes &#x02013; <italic>F5 </italic>(G1691A), <italic>F2 </italic>(G20210A) and <italic>MTHFR </italic>(C677T, A1298C). After evaluating the genetic variants in the aforementioned genes, we selected a subset of individuals who met one of the following criteria: 1. one variant in <italic>F5 </italic>and one in <italic>MTHFR </italic>(fourty-three individuals); 2. one variant in <italic>F2 </italic>and one in <italic>MTHFR </italic>(fifteen individuals) and 3. one variant in <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>(zero individuals). These criteria were chosen to restrict the sample to individuals who would have a higher genetic risk for a thrombotic event, and hence fifty-eight individuals were analysed for <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>polymorphisms.</p></sec><sec><title>Genotyping of <italic>F5 </italic>and <italic>MTHFR </italic>polymorphisms</title><p><italic>F5 </italic>and <italic>MTHFR </italic>polymorphisms (Table <xref ref-type="table" rid="T1">1</xref>) were evaluated by polymerase chain reaction &#x02013; restriction fragment length polymorphism (PCR-RFLP), using three different restriction enzymes: <italic>Mnl</italic>I, <italic>Hinf</italic>I and <italic>Mbo</italic>II (New England Biolabs, Beverly, MA, USA). The genotyping protocol for the detection of the <italic>F5 </italic>polymorphism and <italic>MTHFR </italic>variants was adapted from Kumar <italic>et al</italic>. [<xref ref-type="bibr" rid="B19">19</xref>] and Skibola <italic>et al</italic>. [<xref ref-type="bibr" rid="B20">20</xref>], respectively.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Main characteristics of the seven genetic variants analysed in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Polymorphism</bold></td><td align="center"><bold>Allele variant</bold></td><td align="center"><bold>Amino acid change</bold></td><td align="center" colspan="3"><bold>Gene</bold></td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="left">Location</td><td align="left">Position</td><td align="left">NCBI dbSNP rs#</td></tr></thead><tbody><tr><td align="left">Factor V Leiden</td><td align="left">1691G&#x0003e;A</td><td align="left">R506Q</td><td align="left">1q23</td><td align="left">Exon 10</td><td align="left">rs6025</td></tr><tr><td align="left">Prothrombin</td><td align="left">20210G&#x0003e;A</td><td align="left">NA</td><td align="left">11p11-q12</td><td align="left">3'-UTR</td><td align="left">rs1799963</td></tr><tr><td align="left"><italic>MTHFR</italic></td><td align="left">677C&#x0003e;T</td><td align="left">A222V</td><td align="left">1p36.3</td><td align="left">Exon 5</td><td align="left">rs1801133</td></tr><tr><td></td><td align="left">1298A&#x0003e;C</td><td align="left">E429A</td><td align="left">1p36.3</td><td align="left">Exon 8</td><td align="left">rs1801131</td></tr><tr><td align="left"><italic>CYP2C9*2</italic></td><td align="left">430C&#x0003e;T</td><td align="left">R144C</td><td align="left">10q24.1</td><td align="left">Exon 3</td><td align="left">rs1799853</td></tr><tr><td align="left"><italic>CYP2C9*3</italic></td><td align="left">1075A&#x0003e;C</td><td align="left">I359L</td><td align="left">10q24.1</td><td align="left">Exon 7</td><td align="left">rs1057910</td></tr><tr><td align="left"><italic>VKORC1</italic></td><td align="left">1639G&#x0003e;A</td><td align="left">NA</td><td align="left">16p11.2</td><td align="left">Promoter</td><td align="left">rs9923231</td></tr></tbody></table><table-wrap-foot><p>NA &#x02013; not applicable; UTR &#x02013; untranslated region.</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping of <italic>F2</italic>, <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>polymorphisms</title><p>The genetic tests used for <italic>F2</italic>, <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>(Table <xref ref-type="table" rid="T1">1</xref>) were PTH StripAssay&#x02122; and PGX-Thrombo StripAssay&#x02122; kits (ViennaLab-Labordiagnostika GmbH-Austria), according to the manufacturer's recommendations. These assays are based on reverse hybridization system, using biotin-labelled amplification products to a parallel array of allele-specific oligonucleotides immobilized on a membrane test strip.</p></sec><sec><title>Statistical Analysis</title><p>Allele frequencies were obtained by direct count. Hardy-Weinberg equilibrium was calculated using the Arlequin software v.3.20. This software was used to assess maximum likelihood genetic profiles for thrombotic risk factors, through the expectation maximization algorithm, an iterative procedure from multilocus genotype data with unknown gamete phase. Allele and genotype frequencies were compared between S&#x000e3;o Miguel islanders and mainland Portuguese by &#x003c7;<sup>2 </sup>test using the SPSS software v.17.0. A <italic>p </italic>&#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec><title>Results</title><sec><title>Allele and genotype frequencies of thrombotic genetic risk factors</title><p>Allele and genotype frequencies of <italic>F5 </italic>(G1691A), <italic>F2 </italic>(G20210A) and <italic>MTHFR </italic>(C677T, A1298C) polymorphisms were assessed in 469 healthy individuals from S&#x000e3;o Miguel Island, Azores (Table <xref ref-type="table" rid="T2">2</xref>). All markers were in Hardy-Weinberg equilibrium. The <italic>F5 </italic>variant 1691A frequency was 4.9%, whereas the heterozygous genotype (1691GA) was present at 9.8% (fourty-six individuals). We did not detect 1691AA individuals. The results on the <italic>F2 </italic>analysis show an allele frequency of 1.8% for the 20210A variant. Although this polymorphism is also uncommon in other populations, one homozygous variant individual (0.2%) and fifteen heterozygous (3.2%) were observed in the present study. The frequency of the variant alleles in <italic>MTHFR </italic>(677T and 1298C) was 41.7 and 24.8%, respectively. Overall, 17.9% are 677TT (eighty-four individuals), and 6.0% present the 1298CC genotype (twenty-eight individuals).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Allele and genotype frequencies for thrombotic risk factors and for warfarin pharmacogenetic variants in S&#x000e3;o Miguel population</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Polymorphism</bold></td><td align="center">Allele</td><td align="right">n<sup>a</sup></td><td align="center">Freq.</td><td align="center">Genotype</td><td align="right">n<sup>b</sup></td><td align="center">Freq.</td></tr></thead><tbody><tr><td align="left" colspan="7"><bold>Thrombotic risk variants in general population (N = 469)</bold></td></tr><tr><td align="left"><bold><italic>Factor V Leiden</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">1691G&#x0003e;A</td><td align="center">G</td><td align="right">892</td><td align="center">0.951</td><td align="center">GG</td><td align="right">423</td><td align="center">0.902</td></tr><tr><td></td><td align="center">A</td><td align="right">46</td><td align="center">0.049</td><td align="center">GA</td><td align="right">46</td><td align="center">0.098</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">AA</td><td align="right">0</td><td align="center">0.000</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><italic>Prothrombin</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">20210G&#x0003e;A</td><td align="center">G</td><td align="right">921</td><td align="center">0.982</td><td align="center">GG</td><td align="right">453</td><td align="center">0.966</td></tr><tr><td></td><td align="center">A</td><td align="right">17</td><td align="center">0.018</td><td align="center">GA</td><td align="right">15</td><td align="center">0.032</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">AA</td><td align="right">1</td><td align="center">0.002</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><italic>MTHFR</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">677C&#x0003e;T</td><td align="center">C</td><td align="right">547</td><td align="center">0.583</td><td align="center">CC</td><td align="right">162</td><td align="center">0.345</td></tr><tr><td></td><td align="center">T</td><td align="right">391</td><td align="center">0.417</td><td align="center">CT</td><td align="right">223</td><td align="center">0.475</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">TT</td><td align="right">84</td><td align="center">0.179</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">1298A&#x0003e;C</td><td align="center">A</td><td align="right">705</td><td align="center">0.752</td><td align="center">AA</td><td align="right">264</td><td align="center">0.563</td></tr><tr><td></td><td align="center">C</td><td align="right">233</td><td align="center">0.248</td><td align="center">AC</td><td align="right">177</td><td align="center">0.377</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">CC</td><td align="right">28</td><td align="center">0.060</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left" colspan="7"><bold>Warfarin pharmacogenetic variants in individuals with predisposition to thrombosis (N = 58)</bold></td></tr><tr><td align="left"><bold><italic>CYP2C9</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">430C&#x0003e;T<sup>c</sup></td><td align="center">C</td><td align="right">98</td><td align="center">0.845</td><td align="center">*1/*1</td><td align="right">35</td><td align="center">0.603</td></tr><tr><td></td><td align="center">T</td><td align="right">18</td><td align="center">0.155</td><td align="center">*1/*2</td><td align="right">9</td><td align="center">0.155</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">*2/*2</td><td align="right">2</td><td align="center">0.035</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">1075A&#x0003e;C<sup>c</sup></td><td align="center">A</td><td align="right">104</td><td align="center">0.897</td><td align="center">*1/*3</td><td align="right">7</td><td align="center">0.121</td></tr><tr><td></td><td align="center">C</td><td align="right">12</td><td align="center">0.103</td><td align="center">*2/*3</td><td align="right">5</td><td align="center">0.086</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">*3/*3</td><td align="right">0</td><td align="center">0.000</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><italic>VKORC1</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">1639G&#x0003e;A</td><td align="center">G</td><td align="right">66</td><td align="center">0.569</td><td align="center">GG</td><td align="right">20</td><td align="center">0.345</td></tr><tr><td></td><td align="center">A</td><td align="right">50</td><td align="center">0.431</td><td align="center">GA</td><td align="right">26</td><td align="center">0.448</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">AA</td><td align="right">12</td><td align="center">0.207</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Number of chromosomes</p><p><sup>b </sup>Number of alleles</p><p><sup>c</sup>*1*1 (430CC/1075AA), *1*2 (430CT/1075AA), *1*3 (430CC/1075AC), *2*2 (430TT/1075AA), *2*3 (430CT/1075AC) and *3*3 (430CC/1075CC)</p></table-wrap-foot></table-wrap><p>Twenty-two different genetic profiles for <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>(order in genotype profile) were observed in S&#x000e3;o Miguel's population (Figure <xref ref-type="fig" rid="F1">1</xref>). The frequency of individuals who present a wild-type genotype for all polymorphisms (GG GG CC AA; 11.7%) was almost half of the major profile (GG GG CT AA; 22.4%), differing in heterozygosity for <italic>MTHFR </italic>677CT. Statistical analysis of the combined genotypes demonstrated that there is no significant difference between the present distribution and the hypothetical obtained by Arlequin software (&#x003c7;<sup>2</sup>, <italic>p </italic>= 0.99). No heterozygous or homozygous profiles for all four variants were observed. Almawi <italic>et al. </italic>[<xref ref-type="bibr" rid="B21">21</xref>], reported an OR of 10.5 (95% CI = 4.3&#x02013;25.3) or 6.3 (95% CI = 1.5&#x02013;26.0) for joint occurrence of the <italic>F5 </italic>G1691A or <italic>F2 </italic>G20210A with <italic>MTHFR </italic>677TT genotype, respectively, enhancing the risk for deep vein thrombosis (DVT). Based on this criterion, fifteen (3.2%, <italic>F5</italic>/<italic>MTHFR</italic>) and two individuals (0.4%, <italic>F2</italic>/<italic>MTHFR</italic>) have higher risk for DVT development (Figure <xref ref-type="fig" rid="F1">1</xref> &#x02013; asterisk character; Table <xref ref-type="table" rid="T3">3</xref> &#x02013; bold characters). In general, the joint analysis of all four variants demonstrated that 12.4% of the total sample (58 out of 469) has increased predisposition to thrombosis development.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Combined genotypes for thrombotic risk factors &#x02013; <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>&#x02013; in S&#x000e3;o Miguel population</bold>. Twenty-two different genetic profiles were obtained. Bold characters (blue and black) indicate nucleotide changes compared to the wild-type allele. The asterisk (*) represents the combination of the <italic>F5 </italic>G1691A or <italic>F2 </italic>G20210A with <italic>MTHFR </italic>677TT genotype. Blue bars correspond to the subset of fifty-eight individuals with genetic predisposition to thrombosis selected for warfarin pharmacogenetic study.</p></caption><graphic xlink:href="1477-9560-7-9-1"/></fig><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Warfarin pharmacogenetic profile obtained in the fifty-eight individuals, carriers of at least one variation in <italic>F5 </italic>or <italic>F2 </italic>genes and one in <italic>MTHFR</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="4"><bold>Thrombotic risk factors</bold></td><td align="center" colspan="3"><bold>Warfarin pharmacogenetics</bold></td></tr><tr><td></td><td colspan="4"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center"><italic>F5</italic></td><td align="center"><italic>F2</italic></td><td align="center"><italic>MTHFR</italic></td><td></td><td align="center"><italic>CYP2C9</italic></td><td></td><td align="center"><italic>VKORC1</italic></td></tr><tr><td></td><td colspan="1"><hr></hr></td><td colspan="1"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="1"><hr></hr></td></tr><tr><td align="left"><bold>N (%)</bold></td><td align="center">1691G&#x0003e;A</td><td align="center">20210G&#x0003e;A</td><td align="center">677C&#x0003e;T</td><td align="center">1298A&#x0003e;C</td><td align="center">430C&#x0003e;T</td><td align="center">1075A&#x0003e;C</td><td align="center">1639G&#x0003e;A</td></tr></thead><tbody><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>A</bold><bold><italic>C</italic></bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>C</bold><bold><italic>T</italic></bold></td><td align="center"><bold>A</bold><bold><italic>C</italic></bold></td><td align="center"><bold><italic>AA</italic></bold></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">GG</td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center"><italic>AA</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center"><italic>CC</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">G<italic>A</italic></td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>A</bold><bold><italic>C</italic></bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">GG</td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">GG</td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center"><italic>AA</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>C</bold><bold><italic>T</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td></tr><tr><td align="left">2 (3.5)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>C</bold><bold><italic>T</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>GG</bold></td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center"><italic>AA</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">AA</td><td align="center"><italic>AA</italic></td></tr><tr><td align="left"><bold>3 (5.2)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold><italic>AA</italic></bold></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center"><italic>AA</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center"><italic>AA</italic></td></tr><tr><td align="left"><bold>1 (1.7)</bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold><italic>AA</italic></bold></td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left"><bold>4 (6.9)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center"><italic>AA</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">CC</td><td align="center"><italic>CC</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">2 (3.5)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">AA</td><td align="center">G<italic>A</italic></td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">CC</td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left">3 (5.2)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left">2 (3.5)</td><td align="center">G<italic>A</italic></td><td align="center">GG</td><td align="center">C<italic>T</italic></td><td align="center">A<italic>C</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">CC</td><td align="center"><italic>CC</italic></td><td align="center">CC</td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left">1 (1.7)</td><td align="center">GG</td><td align="center">G<italic>A</italic></td><td align="center">C<italic>T</italic></td><td align="center">AA</td><td align="center">CC</td><td align="center">AA</td><td align="center">GG</td></tr><tr><td align="left"><bold>3 (5.2)</bold></td><td align="center"><bold>G</bold><bold><italic>A</italic></bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>TT</italic></bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>CC</bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>GG</bold></td></tr></tbody></table><table-wrap-foot><p>Italic characters indicate nucleotide changes considering the wild-type allele and in bold illustrate carriers of the <italic>F5 </italic>G1691A or <italic>F2 </italic>G20210A with <italic>MTHFR </italic>677TT genotype conferring high thrombotic risk.</p></table-wrap-foot></table-wrap><p>The comparison of allele frequencies of the thrombotic genetic risk factors &#x02013; <italic>F5</italic>, <italic>F2 </italic>and <italic>MTHFR </italic>&#x02013; in different populations, including S&#x000e3;o Miguel, is depicted in Figure <xref ref-type="fig" rid="F2">2</xref>[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B38">38</xref>]. <italic>F5 </italic>G1691A varies from as low as 0.67% (African-American) to 4.9% (S&#x000e3;o Miguel Island). This trend is not evident for <italic>F2 </italic>G20210A, where the values present a lower range, from 0.3% for African-American to 2.6% for Spanish. African populations showed the lowest frequency for <italic>MTHFR </italic>variants. Taken together, the results demonstrate that, in S&#x000e3;o Miguel, the frequencies for all polymorphisms were similar to those found in Caucasians.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Allele frequencies of the thrombotic risk factors &#x02013; <italic>F5 </italic>(G1691A), <italic>F2 </italic>(G20210A) and <italic>MTHFR </italic>(C677T, A1298C) &#x02013; in different populations, including S&#x000e3;o Miguel</bold>.</p></caption><graphic xlink:href="1477-9560-7-9-2"/></fig></sec><sec><title>Frequencies of pharmacogenetic variants in individuals with genetic predisposition to thrombosis</title><p>In order to understand warfarin pharmacogenetic profile in the fifty-eight individuals, carriers of at least one variation in <italic>F5 </italic>or <italic>F2 </italic>genes and one in <italic>MTHFR</italic>, we studied <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>gene polymorphisms. The allele frequencies for CYP2C9*2 and CYP2C9*3 were 15.5 and 10.3%, respectively (Table <xref ref-type="table" rid="T2">2</xref>). Five genotypes were observed: CYP2C9*1/*1 (60.3%), CYP2C9*1/*2 (15.5%), CYP2C9*1/*3 (12.1%), CYP2C9*2/*2 (3.5%) and CYP2C9*2/*3 (8.6%). The data indicate that 39.7% will require intermediate and/or low warfarin maintenance doses. Regarding the <italic>VKORC1 </italic>gene (G1639A), we identified twenty (34.5%) wild-type individuals, twenty-six (44.8%) heterozygous and twelve (20.7%) homozygous variant, corresponding to an allele frequency of 43.1% for 1639A (Table <xref ref-type="table" rid="T2">2</xref>). These results suggest that 65.5% need intermediate and/or low doses of warfarin.</p><p>The majority of individuals with a genetic predisposition to thrombosis (79.3%, 46 out of 58) carry at least one polymorphism in the genes involved in the metabolism of warfarin (Table <xref ref-type="table" rid="T3">3</xref>). Moreover, the joint analysis of <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>identified a total of thirty-three (57%) individuals that probably will require high doses of warfarin (genotypes: *1*1-GG&#x02192;twelve individuals, *1*1-GA&#x02192;fourteen, *1*2-GG&#x02192;four and *1*3-GG&#x02192;three), and eight (13.8%) will need lower doses (genotypes: *1*2-AA&#x02192;one individual, *1*3-AA&#x02192;one, *2*2-GA&#x02192;two, *2*3-GA&#x02192;one and *2*3-AA&#x02192;three). The remaining seventeen individuals (29.3%) present one of the following genotypes: *1*1-AA&#x02192;nine individuals, *1*2-GA&#x02192;four, *1*3-GA&#x02192;three and *2*3-GG&#x02192;one, where all of them will possibly necessitate intermediate doses. In summary, twenty-five individuals (43.1%) will need intermediate and/or low doses of warfarin, if treatment is started.</p></sec></sec><sec><title>Discussion</title><p>In the general population, individuals may develop thrombosis due to multiple risk factors, acquired and genetic. Clearly, acquired factors (smoking, high cholesterol, obesity, etc.) are more frequent and combined with a genetic predisposition further enhance the risk of a thrombotic event. In the present study, the results obtained from 469 S&#x000e3;o Miguel healthy individuals demonstrate that approximately 5% have the <italic>F5 </italic>1691A allele, the most common hereditary risk factor. Although the frequency found for S&#x000e3;o Miguel is higher than mainland Portuguese, 1% [<xref ref-type="bibr" rid="B22">22</xref>], we did not detect homozygous variant individuals. Nonetheless, the data suggest that S&#x000e3;o Miguel islanders have an increased predisposition to thrombosis and, most probably for CVD. Another inherited cause of thrombosis is the G20210A polymorphism in the <italic>F2 </italic>gene. According to Bosler <italic>et al. </italic>[<xref ref-type="bibr" rid="B39">39</xref>], this variant is weak but a consistent risk factor for DVT and for development of CVD, although to a lesser degree than <italic>F5 </italic>[<xref ref-type="bibr" rid="B4">4</xref>]. The <italic>F2 </italic>results show a lower frequency, 1.8%, when compared to mainland Portugal, 2.5% [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>The most general form of genetic hyperhomocysteinemia results from the <italic>MTHFR </italic>C677T variant, which has a relatively high frequency throughout the world and is considered a low risk factor for vascular diseases [<xref ref-type="bibr" rid="B9">9</xref>]. In S&#x000e3;o Miguel population, <italic>MTHFR </italic>677T shows an allelic frequency of 41.7%, very similar to Europeans (Figure <xref ref-type="fig" rid="F2">2</xref>). According to Almawi <italic>et al. </italic>[<xref ref-type="bibr" rid="B21">21</xref>], <italic>MTHFR </italic>677TT genotype when associated with <italic>F5 </italic>or <italic>F2 </italic>increases the risk of DVT [<xref ref-type="bibr" rid="B20">20</xref>]. Based on these genotypes, the data suggests that 3.6% (seventeen individuals) of the S&#x000e3;o Miguel Island population may have higher risk for developing a thrombotic event. Regarding the 1298C variant, the results were in agreement with those reported by other studies (Figure <xref ref-type="fig" rid="F2">2</xref>), where the polymorphism is also common. We can hypothesise that if the 1298CC individuals have higher plasma homocysteine levels, they will present an enhanced risk for thrombosis.</p><p>The joint analysis of all variants demonstrated that 12.4% of the total sample (58 out of 469) has increased predisposition to thrombosis development. In addition, comparison of allele frequencies for all thrombotic risk factors between S&#x000e3;o Miguel and mainland Portugal revealed statistically significant differences (&#x003c7;<sup>2</sup>, <italic>p </italic>&#x0003c; 0.001). Family-based investigation tends to have biased relative risk estimation, because oversampling of affected individuals is normally present. Therefore, the genetic characterization of disease variants in the general population is important to correct this potential bias. Consequently, the present research will aid the clinical follow-ups of patients with recurrent thrombotic events.</p><p>In today's medicine, the association between pharmacogenetics and drug therapy represents an important tool to treat or control complex diseases. Drug treatment is based on the assumption that a particular dose will yield a predefined blood concentration in circulation and, thereby, establish the desired therapeutic effect [<xref ref-type="bibr" rid="B40">40</xref>]. Recent investigations clearly demonstrate an association between warfarin dose requirements and genetic variations in <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>[<xref ref-type="bibr" rid="B14">14</xref>]. Here, we analysed 58 individuals with genetic predisposition to thrombosis defined by at least one variation in <italic>F5 </italic>or <italic>F2 </italic>genes and one in <italic>MTHFR</italic>. The results obtained show that approximately 60.3% present the genotype <italic>CYP2C9</italic>*1/*1, while the remaining have <italic>CYP2C9</italic>*2 and <italic>CYP2C9</italic>*3 variants. The presence of two copies of the active <italic>CYP2C9</italic>*1 alleles represents the normal metabolic capacity &#x02013; extensive metabolizers (EMs) -, indicating that individuals with this genotype require the highest warfarin maintenance doses [<xref ref-type="bibr" rid="B41">41</xref>].</p><p>Considering S&#x000e3;o Miguel islanders with genetic predisposition to thrombosis, the data of <italic>CYP2C9</italic>*2 and <italic>CYP2C9</italic>*3 alleles demonstrate a close similarity with different European populations [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>]. Individuals who are heterozygous (<italic>CYP2C9</italic>*1/*2 and <italic>CYP2C9</italic>*1/*3) represent a middle range of metabolic activity &#x02013; intermediate metabolizers, IMs [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. The results reveal that, within the fifty-eight subset, 15.5 and 12.1% are IMs, respectively. The <italic>CYP2C9</italic>*2 and <italic>CYP2C9</italic>*3 variants have less activity and metabolize warfarin more slowly. Individuals with one or two of these variations &#x02013; poor metabolizers (PMs) &#x02013; have an enhanced response to warfarin, as well as an increased risk of bleeding when beginning and during treatment if not genotyped previously [<xref ref-type="bibr" rid="B44">44</xref>]. We observed that seven out of fifty-eight individuals are PMs (two with <italic>CYP2C9</italic>*2/*2 and five with <italic>CYP2C9</italic>*2/*3 genotypes; Table <xref ref-type="table" rid="T2">2</xref>). Detecting genetic variations in drug-metabolizing enzymes is useful for identifying individuals who may experience adverse drug reactions (ADRs) with conventional medication doses. Those who are <italic>CYP2C9 </italic>PMs may exhibit different pharmacokinetics than wild-type individuals if they are medicated with warfarin. Consequently, these individuals possibly will require non-conventional doses of drugs that need CYP2C9 enzyme for biotransformation [<xref ref-type="bibr" rid="B45">45</xref>].</p><p>Polymorphisms within <italic>VKORC1</italic>, a target of warfarin inhibition, may explain 23% of this drug dosage variability [<xref ref-type="bibr" rid="B13">13</xref>]. Rieder and colleagues [<xref ref-type="bibr" rid="B13">13</xref>] divided individuals into warfarin high-dose for 1639GG genotype, intermediate-dose for 1639GA and low-dose for 1639AA. This variability is attributed to the fact that the variant lies within the <italic>VKORC1 </italic>promoter, potentially resulting in decreased transcription of the gene product. In general, the results suggest that 65.5% of the fifty-eight individuals with predisposition to thrombosis will require intermediate and/or low doses of warfarin, if treatment is started. Personalized medicine relies on data based on the human genome and disease biology characterization for the development of preventive, diagnostic, and therapeutic strategies that target the underlying determinants of disease in populations with specific molecular profiles [<xref ref-type="bibr" rid="B46">46</xref>]. For this reason, the knowledge obtained from the pharmacogenetic profile in the S&#x000e3;o Miguel's general population is and will be important for the development of patient's individualized therapy, mainly for those who have difficulty to stabilize the warfarin dose.</p></sec><sec><title>Conclusion</title><p>The identification of hereditary risk factors, with appropriate clinical evaluation will allow the informed patient and physician to work together for effective management of thrombosis and prevention of subsequent thrombotic events. The present study demonstrated, for the first time, that S&#x000e3;o Miguel, and possibly the Azores population, shows significant differences on allele frequencies of thrombotic genetic risk factors when compared to mainland Portugal. This research constitutes a primary approach for future studies on CVD, as well as for the implementation of warfarin dosing protocols using the patient's genotypic information.</p></sec><sec><title>Abbreviations</title><p>ADRs: Adverse drug reactions; APC: Activated protein C; CI: Confidence interval; CVD: Cardiovascular diseases; <italic>CYP2C9</italic>: <italic>C</italic>ytochrome P450 2C9 gene; DVT: Deep vein thrombosis; EMs: Extensive metabolizers; <italic>F2</italic>: Prothrombin gene; <italic>F5</italic>: Factor V Leiden gene; IMs: Intermediate metabolizers; <italic>MTHFR</italic>: Methylenetetrahydrofolate reductase gene; OR: Odds Ratio; PCR-RFLP: Polymerase chain reaction &#x02013; restriction fragment length polymorphism; PMs: Poor metabolizers; SNP: Single nucleotide polymorphism; tHcy: Total homocysteine; <italic>VKORC1</italic>: Vitamin K epoxide reductase complex subunit 1 gene; VTE: Venous thromboembolism.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CCB and TP, contributed equally, by performing the experiments, statistical analysis and drafting the manuscript. RC genotyped <italic>MTHFR </italic>variants and PRP participated in the analysis. LMV designed the study, provided scientific orientation and revised the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from Direc&#x000e7;&#x000e3;o Regional da Ci&#x000ea;ncia e Tecnologia of Azores (Ref. M1.2.1/I/002/2008). PRP is funded by grant (Ref. SFRH/BD/27453/2006) from Funda&#x000e7;&#x000e3;o para a Ci&#x000ea;ncia e a Tecnologia of Portugal.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>J</given-names></name><name><surname>Salman</surname><given-names>MM</given-names></name><name><surname>Md</surname><given-names>GH</given-names></name></person-group><article-title>Venous thrombolysis: Current perspectives</article-title><source>Curr Treat Options Cardiovasc Med</source><year>2004</year><volume>6</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">15066245</pub-id><pub-id pub-id-type="doi">10.1007/s11936-004-0044-1</pub-id></citation></ref><ref id="B2"><citation citation-type="other"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Cardiovascular disease: prevention and control (WHO Global Strategy on Diet, Physical Activity and Health)</article-title><source>Recommendations from a Joint Study Group</source><year>2008</year><ext-link ext-link-type="uri" xlink:href="http://www.who.int/en/"/></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group><article-title>Venous thrombosis, a multicausal disease</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1167</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">10209995</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)10266-0</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Dickerman</surname><given-names>JD</given-names></name></person-group><article-title>Hereditary thrombophilia</article-title><source>Thromb J</source><year>2006</year><volume>4</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16420687</pub-id><pub-id pub-id-type="doi">10.1186/1477-9560-4-15</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertina</surname><given-names>RM</given-names></name><name><surname>Reitsma</surname><given-names>RH</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group><article-title>Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis</article-title><source>Thromb Haemost</source><year>1995</year><volume>74</volume><fpage>449</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">8578504</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poort</surname><given-names>SR</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Reitsma</surname><given-names>PH</given-names></name><name><surname>Bertina</surname><given-names>RM</given-names></name></person-group><article-title>A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis</article-title><source>Blood</source><year>1996</year><volume>88</volume><fpage>3698</fpage><lpage>3703</lpage><pub-id pub-id-type="pmid">8916933</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>EA</given-names></name><name><surname>Sturm</surname><given-names>AC</given-names></name><name><surname>Misita</surname><given-names>CP</given-names></name><name><surname>Moll</surname><given-names>S</given-names></name></person-group><article-title>Homocysteine and <italic>MTHFR </italic>mutations. Relation to thrombosis and coronary artery disease</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>e289</fpage><lpage>e293</lpage><pub-id pub-id-type="pmid">15897349</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000165142.37711.E7</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almawi</surname><given-names>WY</given-names></name><name><surname>Ameen</surname><given-names>G</given-names></name><name><surname>Tamim</surname><given-names>H</given-names></name><name><surname>Finan</surname><given-names>RR</given-names></name><name><surname>Irani-Hakime</surname><given-names>N</given-names></name></person-group><article-title>Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase [<italic>MTHFR</italic>] C677T gene polymorphisms in angiographically documented coronary artery disease</article-title><source>J Thromb Thrombolysis</source><year>2004</year><volume>17</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">15353918</pub-id><pub-id pub-id-type="doi">10.1023/B:THRO.0000040489.86029.27</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Den Heijer</surname><given-names>M</given-names></name><name><surname>Lewington</surname><given-names>S</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name></person-group><article-title>Homocysteine, <italic>MTHFR </italic>and risk of venous thrombosis: a meta-analysis of published epidemiological studies</article-title><source>J Thromb Haemost</source><year>2005</year><volume>3</volume><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">15670035</pub-id><pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01141.x</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klerk</surname><given-names>M</given-names></name><name><surname>Verhoef</surname><given-names>P</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Kok</surname><given-names>FJ</given-names></name><name><surname>Shouten</surname><given-names>EG</given-names></name></person-group><article-title><italic>MTHFR </italic>677C&#x0003e;T polymorphism and risk of coronary heart disease. A meta-analysis</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2023</fpage><lpage>2031</lpage><pub-id pub-id-type="pmid">12387655</pub-id><pub-id pub-id-type="doi">10.1001/jama.288.16.2023</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>SA</given-names></name><name><surname>Edelmann</surname><given-names>L</given-names></name><name><surname>Kornreich</surname><given-names>R</given-names></name><name><surname>Desnick</surname><given-names>RJ</given-names></name></person-group><article-title>Warfarin pharmacogenetics: <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations</article-title><source>Am J Hum Genet</source><year>2008</year><volume>82</volume><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">18252229</pub-id><pub-id pub-id-type="doi">10.1016/j.ajhg.2007.10.002</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rettie</surname><given-names>AE</given-names></name><name><surname>Tai</surname><given-names>G</given-names></name></person-group><article-title>The pharmacogenomics of warfarin</article-title><source>Mol Interv</source><year>2006</year><volume>6</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">16960144</pub-id><pub-id pub-id-type="doi">10.1124/mi.6.4.8</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Gage</surname><given-names>BF</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Eby</surname><given-names>CS</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Blough</surname><given-names>DK</given-names></name><name><surname>Thummel</surname><given-names>KE</given-names></name><name><surname>Veenstra</surname><given-names>DL</given-names></name><name><surname>Rettie</surname><given-names>AE</given-names></name></person-group><article-title>Effect of <italic>VKORC1 </italic>haplotypes on transcriptional regulation and warfarin dose</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2285</fpage><lpage>2293</lpage><pub-id pub-id-type="pmid">15930419</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa044503</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wadelius</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Ghori</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Wallerman</surname><given-names>O</given-names></name><name><surname>Melhus</surname><given-names>H</given-names></name><name><surname>Wadelius</surname><given-names>C</given-names></name><name><surname>Bentley</surname><given-names>D</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name></person-group><article-title>Common <italic>VKORC1 </italic>and <italic>GGCX </italic>polymorphisms associated with warfarin dose</article-title><source>Pharmacogenomics J</source><year>2005</year><volume>5</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">15883587</pub-id><pub-id pub-id-type="doi">10.1038/sj.tpj.6500313</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasar</surname><given-names>&#x000dc;</given-names></name><name><surname>Eliasson</surname><given-names>E</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><name><surname>Johansson</surname><given-names>I</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name><name><surname>Sj&#x000f6;qvist</surname><given-names>F</given-names></name></person-group><article-title>Validation of methods for <italic>CYP2C9 </italic>genotyping: frequencies of mutant alleles in a Swedish population</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>254</volume><fpage>628</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">9920790</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1998.9992</pub-id></citation></ref><ref id="B16"><citation citation-type="other"><article-title>Portuguese General Directorate of Health</article-title><ext-link ext-link-type="uri" xlink:href="http://www.dgs.pt/"/></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mota-Vieira</surname><given-names>L</given-names></name><name><surname>Pacheco</surname><given-names>PR</given-names></name><name><surname>Almeida</surname><given-names>AL</given-names></name><name><surname>Cabral</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>J</given-names></name><name><surname>Branco</surname><given-names>CC</given-names></name><name><surname>de Fez</surname><given-names>L</given-names></name><name><surname>Peixoto</surname><given-names>BR</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>AL</given-names></name><name><surname>Mendon&#x000e7;a</surname><given-names>P</given-names></name></person-group><article-title>Human DNA bank in S&#x000e3;o Miguel Island (Azores): A resource for genetic diversity studies</article-title><source>Proceedings of the 21st International ISFG Congress</source><year>2006</year><volume>1288</volume><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.ics.2005.09.174</pub-id></citation></ref><ref id="B18"><citation citation-type="other"><article-title>Portugal National Institute of Statistics</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ine.pt"/></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>SI</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Saraswat</surname><given-names>VA</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name></person-group><article-title>Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study</article-title><source>Indian J Gastroenterol</source><year>2005</year><volume>24</volume><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">16361766</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skibola</surname><given-names>CF</given-names></name><name><surname>Smith</surname><given-names>MT</given-names></name><name><surname>Kane</surname><given-names>E</given-names></name><name><surname>Roman</surname><given-names>E</given-names></name><name><surname>Rollinson</surname><given-names>S</given-names></name><name><surname>Cartwright</surname><given-names>RA</given-names></name><name><surname>Morgan</surname><given-names>G</given-names></name></person-group><article-title>Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukaemia in adults</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>12810</fpage><lpage>12815</lpage><pub-id pub-id-type="pmid">10536004</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.22.12810</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almawi</surname><given-names>WY</given-names></name><name><surname>Tamim</surname><given-names>H</given-names></name><name><surname>Kreidy</surname><given-names>R</given-names></name><name><surname>Timson</surname><given-names>G</given-names></name><name><surname>Rahal</surname><given-names>E</given-names></name><name><surname>Nabulsi</surname><given-names>M</given-names></name><name><surname>Finan</surname><given-names>RR</given-names></name><name><surname>Irani-Hakime</surname><given-names>N</given-names></name></person-group><article-title>A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and <italic>MTHFR </italic>C677T mutations to the genetic susceptibility of deep venous thrombosis</article-title><source>J Thromb Thrombolysis</source><year>2005</year><volume>19</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">16082606</pub-id><pub-id pub-id-type="doi">10.1007/s11239-005-1313-x</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mansilha</surname><given-names>A</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>F</given-names></name><name><surname>Severo</surname><given-names>M</given-names></name><name><surname>Sampaio</surname><given-names>SM</given-names></name><name><surname>Toledo</surname><given-names>T</given-names></name><name><surname>Albuquerque</surname><given-names>R</given-names></name></person-group><article-title>Combined factor V Leiden (R506Q) and prothrombin G20210A genotyping in young patients presenting with deep venous thrombosis</article-title><source>Phlebology</source><year>2006</year><volume>21</volume><fpage>24</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1258/026835506775971171</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauduer</surname><given-names>F</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name></person-group><article-title>Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T and population genetics</article-title><source>Mol Genet Metab</source><year>2005</year><volume>86</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">16185908</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2005.04.002</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arsov</surname><given-names>T</given-names></name><name><surname>Miladinova</surname><given-names>D</given-names></name><name><surname>Spiroski</surname><given-names>M</given-names></name></person-group><article-title>Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels</article-title><source>Croat Med J</source><year>2006</year><volume>47</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">16758522</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Limdi</surname><given-names>NA</given-names></name><name><surname>Beasley</surname><given-names>TM</given-names></name><name><surname>Allison</surname><given-names>DB</given-names></name><name><surname>Rivers</surname><given-names>CA</given-names></name><name><surname>Acton</surname><given-names>RT</given-names></name></person-group><article-title>Racial differences in the prevalence of factor V Leiden mutation among patients on chronic warfarin therapy</article-title><source>Blood Cells Mol Dis</source><year>2006</year><volume>37</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">16889993</pub-id><pub-id pub-id-type="doi">10.1016/j.bcmd.2006.06.003</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franc&#x000e8;s</surname><given-names>F</given-names></name><name><surname>Portol&#x000e8;s</surname><given-names>O</given-names></name><name><surname>Gabriel</surname><given-names>F</given-names></name><name><surname>Corella</surname><given-names>D</given-names></name><name><surname>Sorl&#x000ed;</surname><given-names>JV</given-names></name><name><surname>Sabater</surname><given-names>A</given-names></name><name><surname>Alfonso</surname><given-names>JL</given-names></name><name><surname>Guill&#x000e9;n</surname><given-names>M</given-names></name></person-group><article-title>Factor V Leiden (G1691A) and prothrombin-G20210A alleles among patients with deep venous thrombosis and in the general population from Spain</article-title><source>Rev Med Chil</source><year>2006</year><volume>134</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16532157</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>MC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>So</surname><given-names>WY</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Visvikis</surname><given-names>S</given-names></name><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Fernandez-Cruz</surname><given-names>A</given-names></name><name><surname>Lindpaintner</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>JC</given-names></name></person-group><article-title>Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases</article-title><source>Genomics</source><year>2004</year><volume>83</volume><fpage>559</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">15028278</pub-id><pub-id pub-id-type="doi">10.1016/j.ygeno.2003.09.008</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silingardi</surname><given-names>M</given-names></name><name><surname>Salvarani</surname><given-names>C</given-names></name><name><surname>Boiardi</surname><given-names>L</given-names></name><name><surname>Accardo</surname><given-names>P</given-names></name><name><surname>Silingardi</surname><given-names>M</given-names></name><name><surname>Salvarani</surname><given-names>C</given-names></name><name><surname>Boiardi</surname><given-names>L</given-names></name><name><surname>Accardo</surname><given-names>P</given-names></name><name><surname>Iorio</surname><given-names>A</given-names></name><name><surname>Olivieri</surname><given-names>I</given-names></name><name><surname>Cantini</surname><given-names>F</given-names></name><name><surname>Salvi</surname><given-names>F</given-names></name><name><surname>La Corte</surname><given-names>R</given-names></name><name><surname>Triolo</surname><given-names>G</given-names></name><name><surname>Ciccia</surname><given-names>F</given-names></name><name><surname>Ghirarduzzi</surname><given-names>A</given-names></name><name><surname>Filippini</surname><given-names>D</given-names></name><name><surname>Paolazzi</surname><given-names>G</given-names></name><name><surname>Iori</surname><given-names>I</given-names></name></person-group><article-title>Factor V leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis</article-title><source>Arthritis Rheum</source><year>2004</year><volume>51</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">15077257</pub-id><pub-id pub-id-type="doi">10.1002/art.20237</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antoniadi</surname><given-names>T</given-names></name><name><surname>Hatzis</surname><given-names>T</given-names></name><name><surname>Kroupis</surname><given-names>C</given-names></name><name><surname>Economou-Petersen</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>MB</given-names></name></person-group><article-title>Prevalence of factor V Leiden, prothrombin G20210A and <italic>MTHFR </italic>C677T mutations in a Greek population of blood donors</article-title><source>Am J Hematol</source><year>1999</year><volume>61</volume><fpage>265</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">10440914</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-8652(199908)61:4&#x0003c;265::AID-AJH8&#x0003e;3.0.CO;2-#</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hessner</surname><given-names>MJ</given-names></name><name><surname>Luhm</surname><given-names>RA</given-names></name><name><surname>Pearson</surname><given-names>SL</given-names></name><name><surname>Endean</surname><given-names>DJ</given-names></name><name><surname>Friedman</surname><given-names>KD</given-names></name><name><surname>Montgomery</surname><given-names>RR</given-names></name></person-group><article-title>Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (<italic>MTHFR</italic>) C677T in seven different populations determined by multiplex allele-specific PCR</article-title><source>Thromb Haemost</source><year>1999</year><volume>81</volume><fpage>733</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">10365746</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isshiki</surname><given-names>I</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>R</given-names></name><name><surname>Matsubara</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>N</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name></person-group><article-title>Frequencies of prothrombin 20210 G&#x0003e;A mutation may be different among races studies on Japanese populations with various forms of thrombotic disorders and healthy subjects</article-title><source>Blood Coagul Fibrinol</source><year>1998</year><volume>9</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1097/00001721-199801000-00014</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>R</given-names></name><name><surname>Rivera</surname><given-names>I</given-names></name><name><surname>Ravasco</surname><given-names>P</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Camilo</surname><given-names>ME</given-names></name><name><surname>de Almeida</surname><given-names>IT</given-names></name></person-group><article-title>5,10 &#x02013; Methylenetetrahydrofolate reductase 677C&#x0003e;T and 1298A&#x0003e;C mutations are genetic determinants of elevated homocysteine</article-title><source>QJM</source><year>2003</year><volume>96</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12651974</pub-id><pub-id pub-id-type="doi">10.1093/qjmed/hcg039</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callej&#x000f3;n</surname><given-names>G</given-names></name><name><surname>Mayor-Olea</surname><given-names>A</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>AJ</given-names></name><name><surname>Gait&#x000e1;n</surname><given-names>MJ</given-names></name><name><surname>Palomares</surname><given-names>AR</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>F</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Reyes-Engel</surname><given-names>A</given-names></name></person-group><article-title>Genotypes of the C677T and A1298C polymorphisms of the <italic>MTHFR </italic>gene as a cause of human spontaneous embryo loss</article-title><source>Hum Reprod</source><year>2007</year><volume>22</volume><fpage>3249</fpage><lpage>3254</lpage><pub-id pub-id-type="pmid">17965025</pub-id><pub-id pub-id-type="doi">10.1093/humrep/dem337</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coppede</surname><given-names>F</given-names></name><name><surname>Marini</surname><given-names>G</given-names></name><name><surname>Bargagna</surname><given-names>S</given-names></name><name><surname>Stuppia</surname><given-names>L</given-names></name><name><surname>Minichilli</surname><given-names>F</given-names></name><name><surname>Fontana</surname><given-names>I</given-names></name><name><surname>Colognato</surname><given-names>R</given-names></name><name><surname>Astrea</surname><given-names>G</given-names></name><name><surname>Palka</surname><given-names>G</given-names></name><name><surname>Migliore</surname><given-names>L</given-names></name></person-group><article-title>Folate gene polymorphisms and the risk of Down syndrome pregnancies in young Italian women</article-title><source>Am J Med Genet A </source><year>2006</year><volume>140</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">16596679</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.a.31217</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Regland</surname><given-names>B</given-names></name><name><surname>Palmer</surname><given-names>M</given-names></name><name><surname>Ricksten</surname><given-names>A</given-names></name><name><surname>Palmqvist</surname><given-names>L</given-names></name><name><surname>Rymo</surname><given-names>L</given-names></name><name><surname>Arvanitis</surname><given-names>DA</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos</article-title><source>Eur J Hum Genet</source><year>2002</year><volume>10</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">11938441</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200767</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Caprau</surname><given-names>D</given-names></name><name><surname>Romitti</surname><given-names>P</given-names></name><name><surname>Christensen</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>JC</given-names></name></person-group><article-title>Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes <italic>MTHFR</italic>, <italic>MTHFD</italic>, <italic>MTRR</italic>, <italic>RFC1 </italic>and <italic>GCP2</italic></article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2003</year><volume>67</volume><fpage>545</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">14632302</pub-id><pub-id pub-id-type="doi">10.1002/bdra.10076</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robien</surname><given-names>K</given-names></name><name><surname>Ulrich</surname><given-names>CM</given-names></name></person-group><article-title>5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview</article-title><source>Am J Epidemiol</source><year>2003</year><volume>157</volume><fpage>571</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">12672676</pub-id><pub-id pub-id-type="doi">10.1093/aje/kwg024</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>AS</given-names></name><name><surname>Mahfoud</surname><given-names>Z</given-names></name><name><surname>Taher</surname><given-names>A</given-names></name><name><surname>Zaatari</surname><given-names>G</given-names></name><name><surname>Daher</surname><given-names>R</given-names></name><name><surname>Mahfouz</surname><given-names>RA</given-names></name></person-group><article-title>High prevalence of <italic>MTHFR </italic>gene A1298C polymorphism in Lebanon</article-title><source>Genet Test</source><year>2008</year><volume>12</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18373406</pub-id><pub-id pub-id-type="doi">10.1089/gte.2007.0064</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bosler</surname><given-names>D</given-names></name><name><surname>Mattson</surname><given-names>J</given-names></name><name><surname>Crisan</surname><given-names>D</given-names></name></person-group><article-title>Phenotypic heterogeneity in patients with homozygous prothrombin 20210AA genotype</article-title><source>J Mol Diagn</source><year>2006</year><volume>8</volume><fpage>420</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">16931580</pub-id><pub-id pub-id-type="doi">10.2353/jmoldx.2006.060014</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Schaik</surname><given-names>RH</given-names></name></person-group><article-title>Dose adjustments based on pharmacogenetic of CYP450 enzymes</article-title><source>eJIFCC</source><year>2008</year><volume>19</volume><fpage>41</fpage><lpage>46</lpage></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>AH</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Haller</surname><given-names>C</given-names></name><name><surname>Drake</surname><given-names>K</given-names></name><name><surname>Linder</surname><given-names>M</given-names></name><name><surname>Valdes</surname><given-names>R</given-names><suffix>Jr</suffix></name></person-group><article-title>Dosing algorithm for warfarin using <italic>CYP2C9 </italic>and <italic>VKORC1 </italic>genotyping from a multi-ethnic population: comparison with other equations</article-title><source>Pharmacogenomics</source><year>2008</year><volume>9</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">18370846</pub-id><pub-id pub-id-type="doi">10.2217/14622416.9.2.169</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorado</surname><given-names>P</given-names></name><name><surname>Berecz</surname><given-names>R</given-names></name><name><surname>Norberto</surname><given-names>MJ</given-names></name><name><surname>Yasar</surname><given-names>&#x000dc;</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><name><surname>Llerena</surname><given-names>A</given-names></name></person-group><article-title><italic>CYP2C9 </italic>genotypes and diclofenac, metabolism in Spanish healthy volunteers</article-title><source>Eur J Clin Pharmacol</source><year>2003</year><volume>59</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">12734606</pub-id><pub-id pub-id-type="doi">10.1007/s00228-003-0588-0</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>LE</given-names></name><name><surname>van Vliet</surname><given-names>M</given-names></name><name><surname>van Schaik</surname><given-names>RHN</given-names></name><name><surname>Kasbergen</surname><given-names>AAH</given-names></name><name><surname>De Smet</surname><given-names>PAGM</given-names></name><name><surname>Vulto</surname><given-names>AG</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Stricker</surname><given-names>BH</given-names></name></person-group><article-title>The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon</article-title><source>Pharmacogenetics</source><year>2004</year><volume>14</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15128048</pub-id><pub-id pub-id-type="doi">10.1097/00008571-200401000-00003</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>CK</given-names></name><name><surname>Muto</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name></person-group><article-title><italic>CYP2C9 </italic>and <italic>VKORC1 </italic>genetic polymorphism analysis might be necessary in patients with factor V Leiden and prothrombin gene G2021A mutation(s)</article-title><source>Diagn Mol Pathol</source><year>2007</year><volume>16</volume><fpage>184</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">17721328</pub-id><pub-id pub-id-type="doi">10.1097/PDM.0b013e3180467811</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>A</given-names></name><name><surname>Alfirevic</surname><given-names>A</given-names></name></person-group><article-title>Pharmacogenetics and pharmacogenomics: adverse drug reactions</article-title><source>Pharmacogenomics</source><year>2008</year><volume>9</volume><fpage>1397</fpage><lpage>1401</lpage><pub-id pub-id-type="pmid">18855528</pub-id><pub-id pub-id-type="doi">10.2217/14622416.9.10.1397</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>Y</given-names></name></person-group><article-title>Identification of genetic factors and development of genetic risk diagnosis systems for cardiovascular diseases and stroke</article-title><source>Circ J</source><year>2006</year><volume>70</volume><fpage>1240</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">16998253</pub-id><pub-id pub-id-type="doi">10.1253/circj.70.1240</pub-id></citation></ref></ref-list></back></article> 